{"title":"Predictive Factors for Postrecurrence Survival in Epithelial Ovarian Cancer-a Consecutive Series of 368 Patients and Review of the Literature","authors":"E. Petru","doi":"10.26420/annhematoloncol.2018.1225","DOIUrl":null,"url":null,"abstract":"Purpose: Ovarian cancer is usually diagnosed at advanced stage. Thus, recurrences are common. The aim of this retrospective study was to analyze the prognostic value of selected clinical and biological factors with regard to overall survival after first recurrence. Methods: A total of 368 evaluable patients with primary epithelial cancer of the ovary, fallopian tube or peritoneum were included. Carcinosarcomas, sarcomas and borderline tumors of the ovary, the fallopian tube and the peritoneum were excluded. Patient and tumor characteristics were extracted from hospital records. Recurrence was defined as the first clinical manifestation of tumor progression after an interval of no clinical evidence of disease following primary surgery. Patients with an elevated tumor marker CA125 alone and those who had clinically evident tumor after primary surgery were not eligible for this study. Results: In the multivariate cox regression analysis, five parameters were identified as independent favourable prognostic factors for survival after first recurrence: Time to recurrence ≥ 2 years (p=0.000), Karnofsky status ≥ 80% at the time of recurrence (p=0.008), use of adjuvant chemotherapy (p=0.013), residual disease ≤ 1 cm at primary surgery (p=0.044), and isolated peripheral or paraaortic lymph nodes as localization of first recurrence (p<0.05). Conclusions: Prolonged interval to recurrence seems to be of utmost importance for longer postrecurrence survival. In addition, small or no residual tumor after primary surgery, administration of adjuvant chemotherapy, higher performance status at recurrence and metastases in the peripheral or paraaortic nodes are predictive for improved overall survival.","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hematology & oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26420/annhematoloncol.2018.1225","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Purpose: Ovarian cancer is usually diagnosed at advanced stage. Thus, recurrences are common. The aim of this retrospective study was to analyze the prognostic value of selected clinical and biological factors with regard to overall survival after first recurrence. Methods: A total of 368 evaluable patients with primary epithelial cancer of the ovary, fallopian tube or peritoneum were included. Carcinosarcomas, sarcomas and borderline tumors of the ovary, the fallopian tube and the peritoneum were excluded. Patient and tumor characteristics were extracted from hospital records. Recurrence was defined as the first clinical manifestation of tumor progression after an interval of no clinical evidence of disease following primary surgery. Patients with an elevated tumor marker CA125 alone and those who had clinically evident tumor after primary surgery were not eligible for this study. Results: In the multivariate cox regression analysis, five parameters were identified as independent favourable prognostic factors for survival after first recurrence: Time to recurrence ≥ 2 years (p=0.000), Karnofsky status ≥ 80% at the time of recurrence (p=0.008), use of adjuvant chemotherapy (p=0.013), residual disease ≤ 1 cm at primary surgery (p=0.044), and isolated peripheral or paraaortic lymph nodes as localization of first recurrence (p<0.05). Conclusions: Prolonged interval to recurrence seems to be of utmost importance for longer postrecurrence survival. In addition, small or no residual tumor after primary surgery, administration of adjuvant chemotherapy, higher performance status at recurrence and metastases in the peripheral or paraaortic nodes are predictive for improved overall survival.
目的:卵巢癌通常在晚期被诊断出来。因此,递归是常见的。本回顾性研究的目的是分析选择的临床和生物学因素对首次复发后总生存率的预后价值。方法:共纳入368例可评估的原发性卵巢、输卵管或腹膜上皮癌。排除卵巢、输卵管和腹膜的癌、肉瘤、肉瘤和交界性肿瘤。从医院记录中提取患者和肿瘤特征。复发被定义为原发性手术后一段时间无临床证据后肿瘤进展的第一个临床表现。单纯肿瘤标志物CA125升高的患者和原发性手术后出现临床明显肿瘤的患者不符合本研究的条件。结果:在多变量cox回归分析中,5个参数被确定为首次复发后生存的独立有利预后因素:复发时间≥2年(p=0.000),复发时Karnofsky状态≥80% (p=0.008),使用辅助化疗(p=0.013),原发手术残留病变≤1 cm (p=0.044),孤立的外周或主动脉旁淋巴结作为首次复发的定位(p<0.05)。结论:延长复发间隔似乎对延长复发后生存至关重要。此外,原发性手术后肿瘤小或无残留、给予辅助化疗、复发和外周或主动脉旁淋巴结转移时表现较好是提高总生存率的预测因素。